Literature DB >> 23250766

Inclusion body myositis.

Mazen M Dimachkie1, Richard J Barohn.   

Abstract

Sporadic inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy (IIM) after age 50 years. It presents with chronic insidious proximal leg and distal arm asymmetric muscle weakness. Despite similarities with polymyositis (PM), it is likely that IBM is primarily a degenerative disorder rather than inflammatory muscle disease. IBM is associated with a modest degree of creatine kinase (CK) elevation and an electromyogram (EMG) demonstrates a chronic irritative myopathy. Muscle histopathology demonstrates endomysial inflammatory exudates surrounding and invading non-necrotic muscle fibers often times accompanied by rimmed vacuoles. We review IBM with emphasis on recent developments in the field and discuss ongoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23250766     DOI: 10.1007/s11910-012-0321-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  48 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

Review 3.  Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.

Authors:  Valerie Askanas; W King Engel
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

Review 4.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

5.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Authors:  Fieke M Cox; Maarten J Titulaer; Jacob K Sont; Axel R Wintzen; Jan J G M Verschuuren; Umesh A Badrising
Journal:  Brain       Date:  2011-09-09       Impact factor: 13.501

6.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

7.  Long-term observational study of sporadic inclusion body myositis.

Authors:  Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal:  Brain       Date:  2011-10-12       Impact factor: 13.501

8.  Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

Authors:  R J Barohn; A A Amato; Z Sahenk; J T Kissel; J R Mendell
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

9.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

10.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

View more
  15 in total

1.  Sporadic inclusion body myositis: new insights and potential therapy.

Authors:  Pedro M Machado; Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

Review 2.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 3.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

Review 4.  A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.

Authors:  A M Clerici; G Bono; M L Delodovici; G Azan; G Cafasso; G Micieli
Journal:  Funct Neurol       Date:  2013 Apr-May

5.  Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.

Authors:  Anna Nogalska; Carla D'Agostino; W King Engel; Mafalda Cacciottolo; Shinichi Asada; Kazutoshi Mori; Valerie Askanas
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

6.  Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.

Authors:  Megan K Herbert; Judith Stammen-Vogelzangs; Marcel M Verbeek; Anke Rietveld; Ingrid E Lundberg; Hector Chinoy; Janine A Lamb; Robert G Cooper; Mark Roberts; Umesh A Badrising; Jan L De Bleecker; Pedro M Machado; Michael G Hanna; Lenka Plestilova; Jiri Vencovsky; Baziel G van Engelen; Ger J M Pruijn
Journal:  Ann Rheum Dis       Date:  2015-02-24       Impact factor: 19.103

Review 7.  New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis.

Authors:  Li Alemo Munters; Helene Alexanderson; Leslie J Crofford; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

8.  Targeting protein homeostasis in sporadic inclusion body myositis.

Authors:  Mhoriam Ahmed; Pedro M Machado; Adrian Miller; Charlotte Spicer; Laura Herbelin; Jianghua He; Janelle Noel; Yunxia Wang; April L McVey; Mamatha Pasnoor; Philip Gallagher; Jeffrey Statland; Ching-Hua Lu; Bernadett Kalmar; Stefen Brady; Huma Sethi; George Samandouras; Matt Parton; Janice L Holton; Anne Weston; Lucy Collinson; J Paul Taylor; Giampietro Schiavo; Michael G Hanna; Richard J Barohn; Mazen M Dimachkie; Linda Greensmith
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

Review 9.  Multidisciplinary approach to the management of myopathies.

Authors:  Wendy M King; John T Kissel
Journal:  Continuum (Minneap Minn)       Date:  2013-12

Review 10.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.